Description
A potent DPP-4 inhibitor (Ki = 0.6 nM); inhibits DPP-4 ex vivo (ED50 = 0.12 μmol/kg) in plasma from normal fasted rats; reduces plasma glucose levels in Zuckerfa/fa diabetic rats in a dose-dependent manner when administered orally in doses ranging from 0.3-3 mg/kg; increases plasma insulin levels and improves glucose clearance in ob/ob mice; induces systolic and diastolic dysfunction, reduces contractile force, and exacerbates ischemia-reperfusion injury-induced cardiac dysfunction in isolated guinea pig hearts
Formal name: (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, monohydrochloride
Synonyms: BMS-477118
Molecular weight: 351.9
CAS: 709031-78-7
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Cardiovascular System|Cardiovascular Diseases|Myocardial Infarction||Research Area|Cardiovascular System|Heart|Myocardial Contractility||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity